Intrapulmonary drug delivery of salmon calcitonin

L. J. Deftos; J. J. Nolan; B. L. Seely; P. L. Clopton; G. J. Cote; C. L. Whitham; L. J. Florek; T. A. Christensen; M. R. Hill

doi:10.1007/s002239900345

Intrapulmonary drug delivery of salmon calcitonin

L. J. Deftos, J. J. Nolan, B. L. Seely, P. L. Clopton, G. J. Cote, C. L. Whitham, L. J. Florek, T. A. Christensen, M. R. Hill

Endocrine Neoplasia & HD

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Calcitonin (CT) and other bone-active peptides have been restrained in clinical use by the need for parenteral administration. Although nasal and other transmucosal routes can be used for CT treatment, bioavailability and bioactivity of the peptide thus delivered are limited. We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects. SCT was administered with a dry powder delivery inhaler. For comparison, each subject also received intramuscular (IM) SCT. Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily measured in serum by immunoassay. Compared by dose, IP SCT had 66% of the bioactivity and 28% of the bioavailability of IM SCT. This intrapulmonary route of administration should enhance the clinical acceptability of SCT and could also be applicable to other bone-active peptides.

Original language	English (US)
Pages (from-to)	345-347
Number of pages	3
Journal	Calcified Tissue International
Volume	61
Issue number	4
DOIs	https://doi.org/10.1007/s002239900345
State	Published - Oct 1997

Keywords

Anti-resorptive
Hypercalcemia
Osteopoosis

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Orthopedics and Sports Medicine
Endocrinology

Access to Document

10.1007/s002239900345

Cite this

@article{8c98954c14e94d37bb5f5071289423b2,

title = "Intrapulmonary drug delivery of salmon calcitonin",

abstract = "Calcitonin (CT) and other bone-active peptides have been restrained in clinical use by the need for parenteral administration. Although nasal and other transmucosal routes can be used for CT treatment, bioavailability and bioactivity of the peptide thus delivered are limited. We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects. SCT was administered with a dry powder delivery inhaler. For comparison, each subject also received intramuscular (IM) SCT. Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily measured in serum by immunoassay. Compared by dose, IP SCT had 66% of the bioactivity and 28% of the bioavailability of IM SCT. This intrapulmonary route of administration should enhance the clinical acceptability of SCT and could also be applicable to other bone-active peptides.",

keywords = "Anti-resorptive, Hypercalcemia, Osteopoosis",

author = "Deftos, {L. J.} and Nolan, {J. J.} and Seely, {B. L.} and Clopton, {P. L.} and Cote, {G. J.} and Whitham, {C. L.} and Florek, {L. J.} and Christensen, {T. A.} and Hill, {M. R.}",

year = "1997",

month = oct,

doi = "10.1007/s002239900345",

language = "English (US)",

volume = "61",

pages = "345--347",

journal = "Calcified Tissue International",

issn = "0171-967X",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Intrapulmonary drug delivery of salmon calcitonin

AU - Deftos, L. J.

AU - Nolan, J. J.

AU - Seely, B. L.

AU - Clopton, P. L.

AU - Cote, G. J.

AU - Whitham, C. L.

AU - Florek, L. J.

AU - Christensen, T. A.

AU - Hill, M. R.

PY - 1997/10

Y1 - 1997/10

N2 - Calcitonin (CT) and other bone-active peptides have been restrained in clinical use by the need for parenteral administration. Although nasal and other transmucosal routes can be used for CT treatment, bioavailability and bioactivity of the peptide thus delivered are limited. We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects. SCT was administered with a dry powder delivery inhaler. For comparison, each subject also received intramuscular (IM) SCT. Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily measured in serum by immunoassay. Compared by dose, IP SCT had 66% of the bioactivity and 28% of the bioavailability of IM SCT. This intrapulmonary route of administration should enhance the clinical acceptability of SCT and could also be applicable to other bone-active peptides.

AB - Calcitonin (CT) and other bone-active peptides have been restrained in clinical use by the need for parenteral administration. Although nasal and other transmucosal routes can be used for CT treatment, bioavailability and bioactivity of the peptide thus delivered are limited. We have evaluated the intrapulmonary route (IP) for the delivery of salmon calcitonin (SCT) in normal subjects. SCT was administered with a dry powder delivery inhaler. For comparison, each subject also received intramuscular (IM) SCT. Inhaled SCT produced significant hypocalcemia in all subjects as did injected SCT, and the peptide could be readily measured in serum by immunoassay. Compared by dose, IP SCT had 66% of the bioactivity and 28% of the bioavailability of IM SCT. This intrapulmonary route of administration should enhance the clinical acceptability of SCT and could also be applicable to other bone-active peptides.

KW - Anti-resorptive

KW - Hypercalcemia

KW - Osteopoosis

UR - http://www.scopus.com/inward/record.url?scp=0030885057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030885057&partnerID=8YFLogxK

U2 - 10.1007/s002239900345

DO - 10.1007/s002239900345

M3 - Article

C2 - 9312206

AN - SCOPUS:0030885057

SN - 0171-967X

VL - 61

SP - 345

EP - 347

JO - Calcified Tissue International

JF - Calcified Tissue International

IS - 4

ER -

Intrapulmonary drug delivery of salmon calcitonin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this